A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-08-10
Adverse events
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-28 (study day 31); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 48); relationship: not assessed
Grade 2 Anaemia — outcome: UNKNOWN; onset 2022-10-20 (study day 53); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-01-24 (study day 149); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-03-07 (study day 191); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-03-08 (study day 192); relationship: N
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-11 (study day 195); relationship: N
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 196); relationship: not assessed
Data queries
No data queries.